Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 Earnings Call Transcript March 5, 2026 Kura Oncology, Inc. misses on earnings expectations. Reported EPS is $-0.92 EPS, expectations were $-0.72. Abigail: ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Kura Oncology Inc. (KURA) on Thursday reported a loss of $81 million in its fourth quarter. The San Diego-based company said it had a loss of 92 cents per share. The ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Kura Oncology (KURA) reports results for the quarter ended December 2025. While this widely-known consensus outlook is ...

(FOX 5/KUSI) — The popular conveyor belt sushi chain, Kura Sushi, is expanding its footprint in San Diego. The chain, which currently has one site in the Convoy District, recently announced that it ...

Hello Kitty’s Avocado Dream Donut: Shrimp and creamy avocado over Kura’s special rice, drizzled with pink yuzu cream sauce. The experience will be available from February 1 to February 28, 2026, at ...

CNBC's Jim Cramer talks about small-cap biotech company Kura Oncology and analyzes the company's stock performance. Got a confidential news tip? We want to hear from you. Sign up for free newsletters ...

Kura Oncology has claimed FDA approval for oral menin inhibitor Komzifti for a form of acute myeloid leukaemia (AML), making it the first direct competitor to Syndax's Revuforj, which launched in the ...

Kura Oncology and Kyowa Kirin’s Komzifti has gained FDA approval in adult patients with relapsed or refractory acute myeloid leukaemia (r/r AML) with a NPM1 mutation, joining Syndax’s Revuforj as the ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Kura Oncology (KURA.O), opens new tab and Japanese partner Kyowa Kirin's (4151.T), opens new tab once-daily pill, Komzifti ...

The U.S. Food and Drug Administration on Thursday approved ziftomenib (Komzifti), a leukemia drug developed by Kura Oncology (KURA) with Japanese drugmaker Kyowa Kirin (OTCPK:KYKOF) (OTCPK:KYKOY), ...

The FDA has approved a Kura Oncology drug developed for cases of acute myeloid leukemia (AML) carrying a certain genetic signature, giving the biotech its first commercial asset and the opportunity to ...